MIM
APLT

MetLife Investment Management’s Applied Therapeutics APLT Stock Holding History

MetLife Investment Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-56,302
Closed -$479K – 2814
2024
Q3 		$479K Buy
56,302
+31,724
+129% +$187K ﹤0.01% 1808
2024
Q2 		$115K Buy
+24,578
New +$116K ﹤0.01% 2540
2021
Q4 		– Sell
-7,129
Closed -$118K – 2499
2021
Q3 		$118K Hold
7,129
– – ﹤0.01% 2364
2021
Q2 		$148K Buy
+7,129
New +$135K ﹤0.01% 2332
2021
Q1 		– Sell
-6,292
Closed -$138K – 2315
2020
Q4 		$138K Hold
6,292
– – ﹤0.01% 2160
2020
Q3 		$131K Hold
6,292
– – ﹤0.01% 2092
2020
Q2 		$227K Buy
6,292
+2,261
+56% +$94.6K ﹤0.01% 1830
2020
Q1 		$132K Buy
+4,031
New +$163K ﹤0.01% 1927

Other funds holding APLT

VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

MetLife Investment Management's APLT Position: Q4 2024 in Review

MetLife Investment Management sold out of Applied Therapeutics (APLT) in Q4 2024, closing a stake of 56,302 shares — an estimated $479K sold.

MetLife Investment Management first reported a position in APLT in Q1 2020 and held it in 8 quarters. The position peaked at $479K in Q3 2024. 119 funds tracked by Wall St. Rank hold APLT as of Q4 2024.

  • MetLife Investment Management reported no remaining Applied Therapeutics position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 56,302 Applied Therapeutics shares in Q4 2024, an estimated $479K.
  • MetLife Investment Management first reported a position in Applied Therapeutics in Q1 2020 and held it in 8 quarters.
  • MetLife Investment Management's Applied Therapeutics position peaked at $479K in Q3 2024.
  • 119 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.